AAMU
ABUS icon

Amundi Asset Management US’s Arbutus Biopharma ABUS Stock Holding History

Amundi Asset Management US’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23,400
Closed -$221K – 1588
2018
Q3 		$221K Hold
23,400
– – ﹤0.01% 1448
2018
Q2 		$171K Buy
+23,400
New +$139K ﹤0.01% 1434

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amundi Asset Management US's ABUS Position: Q4 2018 in Review

Amundi Asset Management US sold out of Arbutus Biopharma (ABUS) in Q4 2018, closing a stake of 23,400 shares — an estimated $221K sold.

Amundi Asset Management US first reported a position in ABUS in Q2 2018 and held it in 2 quarters. The position peaked at $221K in Q3 2018. 71 funds tracked by Wall St. Rank hold ABUS as of Q4 2018.

  • Amundi Asset Management US reported no remaining Arbutus Biopharma position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 23,400 Arbutus Biopharma shares in Q4 2018, an estimated $221K.
  • Amundi Asset Management US first reported a position in Arbutus Biopharma in Q2 2018 and held it in 2 quarters.
  • Amundi Asset Management US's Arbutus Biopharma position peaked at $221K in Q3 2018.
  • 71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.